Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Stock Report

| More

AstraZeneca receives marketing permission for Osimertinib

Posted On: 2018-08-09 11:24:35

AstraZeneca Pharma India Limited (AZPIL) today announced that it has received Import & Market permission additional indication for osimertinib (TagrissoTM) Tablet 40 mg and 80 mg, as 1st line treatment for EGFRm advanced Non-Small Cell Lung Cancer (NSCLC) by the Drug Controller General of India (DCGI). The receipt of this permission paves way for the launch of osimertinib in India for 1st line treatment.

Osimertinib is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitutions mutations.

Osimertinib is already approved and available for the treatment of patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an appropriate test, whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy. AstraZeneca has been pioneering access to T790M mutation testing in India through interventions in infrastructure, scientific knowledge dissemination to medical and pathological experts and standardization of test quality through independent External Quality Assurance (EQA) programs.

In 2017, osimertinib was granted 'Breakthrough Therapy' status and 'Priority Review' designations by the US FDA in 1st line treatment setting. osimertinib is a patented product of AstraZeneca group.

Mr. Gagan Singh Bedi, Managing Director, AstraZeneca Pharma India Limited said, "Lung cancer is the leading cause of cancer related mortality in India. Inspite of therapeutic advances, the overall 5-year survival rate of lung cancer is dismal at <5% in India. Tagrisso's approval in first line treatment is an exciting advance in bringing a potential new standard of care to patients with EGFRm advanced NSCLC in India. Clinical data suggests early and sustained benefit with Osimertinib in first line treatment that has the potential to significantly impact long-term patient outcomes and help address the considerable unmet need that remains in the treatment of lung cancer."

Lung cancer is the leading cause of cancer related mortality world-wide and amongst males in India with 5-years survival rates as dismal as 3.7% in India. Various studies have suggested that nearly all the lung cancer cases are non-small cell lung cancers (NSCLC), of which EGFR-TKI sensitising mutations are observed in 23 50% of patients. These patients are particularly sensitive to EGFRTKIs, which block the cell-signaling pathways that drive the growth of tumour cells. However, tumours almost always develop resistance to EGFR-TKI treatment, leading to disease progression.

Nearly 28-54% of EGFRm advanced NSCLC patients, whose disease progresses after treatment with an EGFR TKI, develop resistance due to the T790M resistance mutation. There is also a need for medicines with improved CNS efficacy since approximately 16% patients with EGFRm NSCLC have brain metastases at diagnosis, increasing to approximately half of patients within 3 years of diagnosis.

Osimertinib (Tagrisso) is a third-generation, irreversible EGFR-TKI designed to inhibit both EGFR sensitising (exon 19 deletions or exon 21 (L858R) substitutions mutations) and EGFR T790M resistance mutations, with clinical activity against CNS metastases.

Shares of ASTRAZENECA PHARMA INDIA LTD. was last trading in BSE at Rs.1735 as compared to the previous close of Rs. 1710.15. The total number of shares traded during the day was 6483 in over 975 trades.

The stock hit an intraday high of Rs. 1808.85 and intraday low of 1710. The net turnover during the day was Rs. 11391871.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Poddar Pigments Ltd Q2 net profit drops to Rs. 3.73 crore

IndiGrid: Stability amidst Volatility

Oriental Bank of Commerce board to approve Q2, H1 results on Oct 25, 2018

Greenlam Industries Ltd board to announce Q2 results on Oct 26, 2018

Shalimar Paints Ltd calls for board meeting on Oct 25, 2018

Summit Securities Ltd calls for board meeting on Oct 31, 2018

Jubilant Industries Ltd board to consider Q2 results, preferential issue on Oct 25, 2018

Prakash Industries Ltd board to consider 2nd quarter results on Oct 29, 2018

Newgen Software Technologies Ltd board to approve Q2 results on Oct 29, 2018

Indiabulls Real Estate Ltd calls for board meeting on Oct 24, 2018

Munjal Showa Ltd board to announce 2nd quarter results on Nov 3, 2018

Zydus receives tentative approval from the USFDA for Colchicine Tablets

DCM Shriram Ltd calls for board meeting on Oct 29, 2018 to consider Q2 results

JTEKT India Ltd board to approve quarterly results on Nov 6, 2018

Lemon Tree Hotels Ltd board to announce Q2 results on Nov 13, 2018

NITCO Ltd calls for board meeting on Oct 30, 2018

BHEL board to consider Q2 FY19 results on Oct 25, 2018

Sintex Industries Ltd board to consider second quarter results on Oct 27, 2018

Minda Corporation Ltd board to announce quarterly results on Oct 31, 2018

Reliance Industries Ltd Q2 FY19 results review

Godawari Power & Ispat Ltd board to approve Q2 results on Oct 26, 2018

Nava Bharat Ventures Ltd calls for board meeting on Nov 3, 2018

Sintex Plastics Technology Ltd board to announce Q2, H1 FY19 results on Oct 26, 2018

Insilco Ltd board to approve 2nd quarter results on Nov 12, 2018

iGTB and Bolero International Partner for Revenue Enablement and Capital Optimisation for Trade Finance and Supply Chain Finance Solutions

Samkrg Pistons & Rings Ltd board to consider Q2 results on Oct 29, 2018

Reliance Industries Ltd announces Q2 FY19 results

5paisa Capital - Income for Q2FY19 at Rs. 1,274 Lakhs - up 41% q-o-q and 205% y-o-y

DCB Bank announces Second Quarter FY 2019 Results

Gujarat Industries Power Company Ltd calls for board meeting on Nov 1, 2018

Ganesh Films India Ltd acquires theatrical rights of Ezhumin for North India

Reliance Industries announces strategic investment in Den Networks Ltd and Hathway Cable and Datacom Ltd

Today at the 10th annual Connected Health Conference, Partners

ACC Ltd - Highlights of July-September 2018

ICRA Ltd calls for board meeting on Nov 1, 2018 to consider Q2 results

Reliance Industries arm makes strategic investment in SkyTran Inc

Escorts Ltd board to consider Q2 results on Oct 31, 2018

LKP Securities Ltd board to approve 2nd quarter results on Oct 30, 2018

Vijaya Bank board to announce quarterly results on Oct 29, 2018

InterGlobe Aviation Ltd calls for board meeting on Oct 24, 2018

Geojit Financial Services Ltd board to consider Q2, H1 FY19 results on Oct 24, 2018

Dish TV India Ltd board to announce second quarter results on Oct 25, 2018

G N A Axles Ltd approves availing fresh term loan of Rs. 60 crores

Piramal Enterprises Ltd board to approve 2nd quarter results on Oct 25, 2018

Wockhardt Ltd board to consider Q2 FY19 results on Nov 10, 2018

ICICI Home Finance Company Ltd H1FY19 net profit slides to Rs. 37.99 crore

Reliance Jio Infocomm Ltd reports net profit of Rs. 1293 crore in H1FY19

Mahindra Rural Housing Finance Ltd posts H1FY19 PAT of Rs. 90.91 crore

ACC Ltd Q3 CY18 net profit higher at Rs. 209.14 crore

Reliance Industries Ltd Q2 FY19 PAT jumps to Rs. 9549 crores







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2018